{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T14:13:32Z","timestamp":1786889612853,"version":"build-2736575974"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"abstract":"<jats:p>\n                    The causal relationship between immune cell signatures and multiple myeloma (MM) pathobiology remains incompletely understood. This study aimed to explore the bidirectional causal associations between 731 circulating immune cell traits and MM risk using a two-sample, bidirectional Mendelian randomization (MR) approach. Two-sample MR analyses were conducted utilizing genome-wide association study (GWAS) summary statistics for 731 immune cell phenotypes and MM GWAS datasets. Sensitivity analyses were performed to assess the robustness and reliability of the findings. Furthermore, meta-analyses were conducted on specific immune cell traits identified through the primary MR analyses to reinforce causal inferences. We identified 11 immune cell traits across 3 immune profiles \u2013 absolute cell count (AC), relative cell (RC) frequency, and median fluorescence intensity (MFI) \u2013 that exhibited significant causal associations with MM. Three immune traits were associated with an increased risk of MM: CD39\n                    <jats:sup>+<\/jats:sup>\n                    CD8br %CD8br (\n                    <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>\n                    &lt;\u2005.001), CD20 on CD20\n                    <jats:sup>\u2212<\/jats:sup>\n                    CD38\n                    <jats:sup>\u2212<\/jats:sup>\n                    cells (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002), and CD38 on transitional cells (\n                    <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>\n                    &lt;\u2005.001). Conversely, 8 immune traits were found to confer a protective effect against MM, including CD11c\n                    <jats:sup>+<\/jats:sup>\n                    monocyte AC (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002), Im myeloid-derived suppressor cell (MDSC) %CD33\n                    <jats:sup>dim<\/jats:sup>\n                    HLA-DR\n                    <jats:sup>\u2212<\/jats:sup>\n                    CD66b\n                    <jats:sup>\u2212<\/jats:sup>\n                    (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002), CD8\n                    <jats:sup>dim<\/jats:sup>\n                    %T cell (\n                    <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>\n                    &lt;\u2005.001), CD8\n                    <jats:sup>dim<\/jats:sup>\n                    %leukocyte (\n                    <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>\n                    &lt;\u2005.001), CD24 on CD24\n                    <jats:sup>+<\/jats:sup>\n                    CD27\n                    <jats:sup>+<\/jats:sup>\n                    cells (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.003), CD4 on naive CD4\n                    <jats:sup>+<\/jats:sup>\n                    cells (\n                    <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>\n                    &lt;\u2005.001), CD11b on Mo MDSCs (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002), and HLA-DR on CD33\n                    <jats:sup>dim<\/jats:sup>\n                    HLA-DR\n                    <jats:sup>+<\/jats:sup>\n                    CD11b\n                    <jats:sup>\u2212<\/jats:sup>\n                    cells (\n                    <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>\n                    &lt;\u2005.001). The reverse MR analysis demonstrated a significant causal association between the expression of CD19 on CD24\n                    <jats:sup>+<\/jats:sup>\n                    CD27\n                    <jats:sup>+<\/jats:sup>\n                    B cells and CD16 on CD14\n                    <jats:sup>+<\/jats:sup>\n                    CD16\n                    <jats:sup>+<\/jats:sup>\n                    monocytes in MM. These findings were validated through sensitivity tests and meta-analyses, which confirmed the robustness of the results and the absence of significant heterogeneity. Our bidirectional MR analyses provide compelling evidence for causal relationships between specific immune cell phenotypes and MM risk. These insights deepen the understanding of immune system dysregulation in MM pathogenesis and highlight potential immune-related targets for future therapeutic interventions.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044276","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:03:45Z","timestamp":1757354625000},"page":"e44276","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Exploring multiple myeloma pathobiology and immune cell signatures: Evidence from bidirectional genetic analysis"],"prefix":"10.1097","volume":"104","author":[{"given":"Ying","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Beijing Haidian Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251029","first-page":"7","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20251029","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"R3-20251029","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study.","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"R4-20251029","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma.","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20251029","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline.","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"key":"R6-20251029","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma.","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-20251029","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma.","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"key":"R8-20251029","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/EBC20160017","article-title":"The immune system.","volume":"60","author":"Nicholson","year":"2016","journal-title":"Essays Biochem"},{"key":"R9-20251029","doi-asserted-by":"crossref","first-page":"157496","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression.","volume":"2012","author":"Manier","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"R10-20251029","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","article-title":"Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.","volume":"6","author":"Schinke","year":"2022","journal-title":"Blood Adv"},{"key":"R11-20251029","doi-asserted-by":"crossref","first-page":"15662","DOI":"10.1038\/s41598-025-00074-7","article-title":"Bioinformatics analysis of intrinsic drivers of immune dysregulation in multiple myeloma to elucidate immune phenotypes and discover prognostic gene signatures.","volume":"15","author":"Fang","year":"2025","journal-title":"Sci Rep"},{"key":"R12-20251029","doi-asserted-by":"crossref","first-page":"1584350","DOI":"10.3389\/fimmu.2025.1584350","article-title":"Decoding multiple myeloma: single-cell insights into tumor heterogeneity, immune dynamics, and disease progression.","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"R13-20251029","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1038\/bcj.2016.118","article-title":"A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.","volume":"6","author":"Botta","year":"2016","journal-title":"Blood Cancer J"},{"key":"R14-20251029","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma.","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"R15-20251029","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"key":"R16-20251029","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.","volume":"128","author":"Kawano","year":"2018","journal-title":"J Clin Invest"},{"key":"R17-20251029","doi-asserted-by":"crossref","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"R18-20251029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Smith","year":"2003","journal-title":"Int J Epidemiol"},{"key":"R19-20251029","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/rssa.12343","article-title":"Mendelian randomization: methods for using genetic variants in causal estimation.","volume":"181","author":"Little","year":"2018","journal-title":"J R Stat Soc Ser A: Stat Soc"},{"key":"R20-20251029","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy.","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat Genet"},{"key":"R21-20251029","doi-asserted-by":"crossref","first-page":"e1009238","DOI":"10.1371\/journal.pcbi.1009238","article-title":"Ten simple rules for conducting a mendelian randomization study.","volume":"17","author":"Gagliano Taliun","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"R22-20251029","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement.","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"R23-20251029","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jrsm.1346","article-title":"Meta-analysis and Mendelian randomization: a review.","volume":"10","author":"Bowden","year":"2019","journal-title":"Res Synth Methods"},{"key":"R24-20251029","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1097\/JS9.0000000000001327","article-title":"Complex causal association between genetically predicted 731 immunocyte phenotype and osteonecrosis: a bidirectional two-sample Mendelian randomization analysis.","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"R25-20251029","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies.","volume":"40","author":"Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"key":"R26-20251029","doi-asserted-by":"crossref","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.1","article-title":"Guidelines for performing Mendelian randomization investigations: update for summer 2023.","volume":"4","author":"Burgess","year":"2019","journal-title":"Wellcome Open Res"},{"key":"R27-20251029","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1177\/0962280215597579","article-title":"A review of instrumental variable estimators for Mendelian randomization.","volume":"26","author":"Burgess","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"R28-20251029","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method.","volume":"32","author":"Burgess","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"R29-20251029","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol Rev"},{"key":"R30-20251029","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation.","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol Med"},{"key":"R31-20251029","doi-asserted-by":"crossref","first-page":"e1005177","DOI":"10.1371\/journal.ppat.1005177","article-title":"CD39 expression identifies terminally exhausted CD8+ T cells.","volume":"11","author":"Gupta","year":"2015","journal-title":"PLoS Pathog"},{"key":"R32-20251029","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1158\/2159-8290.CD-19-0541","article-title":"Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity.","volume":"9","author":"Li","year":"2019","journal-title":"Cancer Discov"},{"key":"R33-20251029","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1172\/JCI40231","article-title":"CD20 deficiency in humans results in impaired T cell-independent antibody responses.","volume":"120","author":"Kuijpers","year":"2010","journal-title":"J Clin Invest"},{"key":"R34-20251029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future.","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"R35-20251029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: an update.","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"key":"R36-20251029","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.","volume":"126","author":"Leone","year":"2015","journal-title":"Blood"},{"key":"R37-20251029","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment.","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"R38-20251029","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO;2-O","article-title":"Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation.","volume":"27","author":"Caruso","year":"1997","journal-title":"Cytometry"},{"key":"R39-20251029","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1084\/jem.188.9.1679","article-title":"Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells.","volume":"188","author":"Klein","year":"1998","journal-title":"J Exp Med"},{"key":"R40-20251029","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults.","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"R41-20251029","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1074\/jbc.M406968200","article-title":"Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2.","volume":"280","author":"Solovjov","year":"2005","journal-title":"J Biol Chem"},{"key":"R42-20251029","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation.","volume":"15","author":"Roche","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R43-20251029","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"R44-20251029","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cyto.b.21269","article-title":"Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.","volume":"90","author":"Pojero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"R45-20251029","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2014.00257","article-title":"Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.","volume":"5","author":"Tete","year":"2014","journal-title":"Front Immunol"},{"key":"R46-20251029","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nri3582","article-title":"The function of Fc\u03b3 receptors in dendritic cells and macrophages.","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R47-20251029","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/imt-2016-0135","article-title":"Tumor-associated macrophages: implications in cancer immunotherapy.","volume":"9","author":"Petty","year":"2017","journal-title":"Immunotherapy"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:02:47Z","timestamp":1761746567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":47,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044276","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"2025-05-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}